Illumigen Biosciences Acquired by Cubist Pharmaceuticals

Illumigen Biosciences of Seattle, a spinoff company from the University of Washington Genome Center, was recently acquired by Cubist Pharmaceuticals of Lexington, Mass. Illumigen’s prospective drug to treat Hepatitis C virus was the basis of the acquisition. Illumigen was formed in 2000 by faculty/staff from the Genome Center (housed in the Washington Technology Center facility).

Related external links (will open a new window):

  • Read the Cubist press release

    – end of post –

  • This entry was posted in Company_and_Client_News, UW. Bookmark the permalink.

    Leave a Reply

    Fill in your details below or click an icon to log in:

    WordPress.com Logo

    You are commenting using your WordPress.com account. Log Out /  Change )

    Google photo

    You are commenting using your Google account. Log Out /  Change )

    Twitter picture

    You are commenting using your Twitter account. Log Out /  Change )

    Facebook photo

    You are commenting using your Facebook account. Log Out /  Change )

    Connecting to %s